Description
PD-1 [Biotinylated]: PD-L1 Inhibitor Screening ELISA Kit | EP-101| Gentaur Distribution US, UK & Europe
Immune checkpoint pathway is a focal point of today’s cancer research. PD-1 is one of the best characterized checkpoint proteins. The binding between PD-1 and its ligand PD-L1 suppresses T-cell activation and allows cancer cells to escape from body’s immune surveillance. Therefore, the pharmaceutical inhibition of PD-1 or its ligand has been considered a promising strategy by many oncologists.
Source: Immune checkpoint pathway is a focal point of today’s cancer research. PD-1 is one of the best characterized checkpoint proteins. The binding between PD-1 and its ligand PD-L1 suppresses T-cell activation and allows cancer cells to escape from body’s immune surveillance. Therefore, the pharmaceutical inhibition of PD-1 or its ligand has been considered a promising strategy by many oncologists.
Molecule: PDN/A1 & PDN/AL1.
Format: Solid.
Species: Human.
Application: This kit is developed for screening for inhibitors of human PD-1 binding to human PD-L1.
Kit Component: This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new PD-1 pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human PD-1 to immobilized human PD-L1 in a functional ELISA assay, and employs a simple colorimetric sandwich ELISA platform.
Stability: The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C.
Storage Conditions: 2-8℃.
Shipping Conditions: RT